Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy
Top Cited Papers
Open Access
- 6 April 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 305 (13), 1305-1314
- https://doi.org/10.1001/jama.2011.382
Abstract
The Women's Health Initiative (WHI) Estrogen-Alone Trial was a double-blind, placebo-controlled, randomized clinical trial evaluating the effects of conjugated equine estrogens (CEE) on chronic disease incidence among postmenopausal women with prior hysterectomy. The trial intervention was stopped 1 year early after a mean of 7.1 years of follow-up because of an increased risk of stroke and little likelihood of altering the balance of risk to benefit by the planned termination date. Analyses of outcomes during the intervention period suggested that treatment effects differed by age; compared with older women, younger women receiving CEE had a lower risk of coronary heart disease (CHD), colorectal cancer, total death, and the global index of chronic diseases.1 However, the tests for interaction of age with treatment were only statistically significant for colorectal cancer.1Keywords
This publication has 39 references indexed in Scilit:
- Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk AssessmentObstetrics & Gynecology, 2004
- Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened PopulationJournal of Clinical Oncology, 2003
- Outcomes ascertainment and adjudication methods in the women's health initiativeAnnals of Epidemiology, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal WomenJAMA, 2003
- Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast CancerJAMA, 2003
- Understanding the Divergent Data on Postmenopausal Hormone TherapyNew England Journal of Medicine, 2003
- Bone Mass Response to Discontinuation of Long-term Hormone Replacement TherapyResults From the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up StudyArchives of Internal Medicine, 2002
- Estrogen replacement therapy, atherosclerosis, and vascular functionCardiovascular Research, 2002
- Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer RiskJAMA, 2000